HYDERABAD: Dr Reddy's Laboratories Limiteds consolidated profit after tax for the quarter-ended March 31, 2019 was up by 44% at ₹434.4 crore against ₹302.2 crore in the third quarter of FY 18, a senior official of the city-based drug maker said Friday. President, CFO and global head (HR) of Dr Reddys Saumen Chakraborty in a press conference said the revenue for the quarter under discussion was up by 14% at ₹4,017 crore against ₹3,535 crore in the same quarter last fiscal. Those from North America grew by three per cent to ₹1,496 crore against ₹1,449 crore in Q4 of FY18. Dr Reddy's relaunched its buprenorphine and naloxone sublingual film, the generic version of suboxone in the USA market in February 2019 at risk. Indivior unsuccessfully contested in courts on the launch of Dr Reddys drug.

Source: Mint May 17, 2019 14:03 UTC